Red blood cell transfusion practice and cardiac comorbidities in patients with myelodysplastic syndromes
Transfusion · 2025
DOI: 10.1111/trf.18391 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transfusion, 2025. Verfasst von Allison Mo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Transfusion Research Unit, School of Public Health & Preventive Medicine, Faculty of Medicine, Nursing & Health Sciences, Monash University, Melbourn…. Hauptthemen laut MEDLINE: Erythrocyte Transfusion, Myelodysplastic Syndromes, Heart Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, Monash University, National Blood Authority.
Abstract (Originalsprache)
Background
Evidence guiding optimal transfusion practice for patients with myelodysplastic syndromes (MDS) is lacking. Many patients have concurrent cardiac disease. Data on practice are sparse. We aimed to describe the use of red blood cell (RBC) transfusion and the prevalence of cardiac comorbidities in patients with MDS within Australia's largest public hospital network to better understand real‐world practices and outcomes.
Methods
We conducted a retrospective cohort study of patients aged ≥18 years with MDS, MDS/myeloproliferative overlap neoplasm or chronic myelomonocytic leukemia admitted from 2016 to 2018 to determine RBC transfusion‐related endpoints.
Results
One hundred and seventy‐nine patients (median age 78 years, 61.5% male) were included, with a median follow‐up of 46 weeks. Of these, 102 (57.0%) received RBC transfusion. Transfused patients had lower presenting Hb (87 vs. 105 g/L, p < 0.0001), higher rates of cardiac disease (29.4% vs. 12.9%, p = 0.009) and 5‐azacytidine use (31.4% vs. 13.0%, p = 0.004). Sixty‐five patients (36.3%) received outpatient RBC transfusions, with a median of 2 units RBC per transfusion and 14 days between transfusions. The median pre‐transfusion Hb was 80 g/L (IQR 74–86 g/L). Forty patients (22.4%) had evidence of cardiac disease, with similar pre‐transfusion Hb for patients with and without cardiac disease (median Hb 79 g/L vs. 81 g/L, p = 0.1).
Discussion
Patients with MDS frequently require RBC transfusion, and restrictive transfusion strategies predominate despite many patients having cardiac comorbidities. Further research is needed to address optimal transfusion strategies in such patients and associated cardiac outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Transfusion Research Unit, School of Public Health & Preventive Medicine, Faculty of Medicine, Nursing & Health Sciences, Monash University, Melbourne, Australia.
- Monash Hematology, Monash Health, Melbourne, Australia.
- Austin Pathology and Department of Haematology, Austin Health, Melbourne, Australia.
- Department of Medicine, School of Clinical Sciences, Faculty of Medicine, Nursing & Health Sciences, Monash University, Melbourne, Australia.
- Department of Haematology, Alfred Health, Melbourne, Australia.
ORCID-Profile: Allison Mo, Zoe K McQuilten
Förderung
- National Health and Medical Research Council
- Monash University
- National Blood Authority
- Haematology Society of Australia and New Zealand
Zitieren
APA
Mo, A., Wood, E. M., Shortt, J., & McQuilten, Z. K. (2025). Red blood cell transfusion practice and cardiac comorbidities in patients with myelodysplastic syndromes. Transfusion. https://doi.org/10.1111/trf.18391
Vancouver
Mo A, Wood EM, Shortt J, McQuilten ZK. Red blood cell transfusion practice and cardiac comorbidities in patients with myelodysplastic syndromes. Transfusion. 2025. doi:10.1111/trf.18391
BibTeX
@article{Mo2025,
author = {Mo, Allison and Wood, Erica M and Shortt, Jake and McQuilten, Zoe K},
title = {Red blood cell transfusion practice and cardiac comorbidities in patients with myelodysplastic syndromes},
journal = {Transfusion},
year = {2025},
doi = {10.1111/trf.18391}
}
EUVIMED